Higher levels of Ki-67 have been reported in HER2-positive and triple-negative breast cancers compared with HER2-negative luminal tumors, particularly compared to luminal A disease [64,65,66]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.